Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 44.79M P/E - EPS this Y 51.50% Ern Qtrly Grth -
Income -35.81M Forward P/E -1.58 EPS next Y 15.40% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 3.40 EPS next 5Y - 52W High Chg -72.00%
Recommedations 1.70 Quick Ratio 1.28 Shares Outstanding 57.75M 52W Low Chg 35.00%
Insider Own 0.27% ROA -84.60% Shares Float 54.30M Beta 2.41
Inst Own 14.26% ROE -313.39% Shares Shorted/Prior 9.72M/7.55M Price 1.58
Gross Margin - Profit Margin - Avg. Volume 154,591 Target Price 5.83
Oper. Margin - Earnings Date Aug 8 Volume 138,762 Change -3.66%
About SELLAS Life Sciences Group, Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc News
07/16/24 SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
07/08/24 SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
06/24/24 SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
06/17/24 SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
06/10/24 SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
05/22/24 Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
05/14/24 SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
05/01/24 SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
04/29/24 SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
03/28/24 SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
06:35 AM SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
03/19/24 SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
03/19/24 SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
03/15/24 SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
03/08/24 SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
03/01/24 SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
02/29/24 SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
02/06/24 SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
01/25/24 SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
01/10/24 SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS Chatroom

User Image Notanymore Posted - 2 hours ago

$SLS Sellas…. IF …. You ever are presented with a strong buyout offer…. Please consider retail investors … who I think (at least I would) prefer an all stock deal to control capital gains. Thank you Good luck to patients!

User Image pierrules Posted - 3 hours ago

$SLS Go team USA 🇺🇸

User Image Pingouin Posted - 5 hours ago

$SLS this stock is a fucking joke

User Image CARTE_BLANCHE_DEVEREAUX Posted - 6 hours ago

$SLS @rudazur2 getting those horny eyes... edging himself all weekend ready to get railed by green days.

User Image alaskawing Posted - 6 hours ago

$SLS

User Image Grb1 Posted - 6 hours ago

$SLS How about BMY today! Another potential suitor? Opdivo may need a companion????

User Image Thestokinator Posted - 6 hours ago

$SLS they can only lend if u gave marginal account or you tell them to lend it! i was very clear NO fucking way!

User Image JakeDelToro Posted - 7 hours ago

$SLS we really closed at 1.17😅 I fuckin love it Added a few hundred shares today. I’ve finalized my jan call position, i am only buying shares from here on.

User Image CARTE_BLANCHE_DEVEREAUX Posted - 7 hours ago

$SLS $DXCM Just so everybody knows, the buyout is pretty much guaranteed for Monday morning pre-market as I sold a large portion of my SLS position here to buy some calls on dxcm. I couldn't resist, crazy market overreaction to missing a beat. Hoping for a bounce on monday, and then be back into SLS with that money... but of course you know what happens then.

User Image cb5000calls Posted - 8 hours ago

$SLS 10.5K buy after hours.... what's wrong shorty you don't want to hold over the weekend paying 406% borrow fees...

User Image OK_USA Posted - 8 hours ago

$SLS heat is up on the shorts. Once shorts get cooked, they will taste wonderful. Have a good weekend.

User Image smokinMcds Posted - 8 hours ago

$SLS and just like that, we are 1 day closer. Enjoy the weekend folks, payday right around the corner. Shares are locked

User Image buy_and_pray Posted - 8 hours ago

$SLS did you fall on your head as a baby? i am telling people who DO use them to email them. if you don't use them, then don't email them...?

User Image KidDynomike Posted - 8 hours ago

$SLS not everyone uses public.com. If i email them, it means nothing to them bc they do not know me

User Image PaulNipkow Posted - 8 hours ago

$SLS Let's walk before start running. Sls will need time and it may happen in future - but not overnight. Stay and hold !

User Image buy_and_pray Posted - 8 hours ago

$SLS LOL okay

User Image KidDynomike Posted - 8 hours ago

$SLS scam and lie!!!

User Image cb5000calls Posted - 8 hours ago

$SLS now number #24 on the list of highest borrow fee stocks... 406.162% For a micro-cap of only $67 million, getting ready to report Phase 3 Regal AML interim analysis, this is highly comical. REG SHO threshold is engaged, and shorts are officially trapped. https://companiesmarketcap.com/companies-with-the-highest-cost-to-borrow/ $SPY $QQQ $NASDAQ

User Image buy_and_pray Posted - 9 hours ago

$SLS Longtime listener, first time caller to this board. Been holding SLS for 3.5 years now and I'm using my first post to say I stopped my public account from share lending. You just send an email to [email protected] with the subject "securities lending opt-out" and they'll handle it within a day or so - doing my part to help :)

User Image MrBlockchain Posted - 9 hours ago

$SLS I don't know who pi$$ed off this MM, but damned if he isn't gonna show us who's in charge.

User Image OK_USA Posted - 9 hours ago

$SLS shorts will soon feel the pain...it is imminent.

User Image GPS_OS_21_vs_SOC_5 Posted - 9 hours ago

$SLS Pr for sls009 partnership / license deal incoming any day, in addition to the phase 3 trial results, again any day and within this quarter, at the latest per the idmc, the only dr’s who see the actual unblinded data, and who just weighed for the 1st time to define the timeline. Read @ccx post on the CE0 Statements re Stifle negotiating the 009 Deal.

User Image SusieLee Posted - 9 hours ago

$SLS 10 more years

User Image cb5000calls Posted - 9 hours ago

$SLS shorts now losing 1.11% per day by refusing to close out their 9 million plus short shares hahahah you are going to lose 3.33% just holding over the weekend while the market is closed from Friday-Sunday hahahahahaah priceless.

User Image CantHoldForever Posted - 9 hours ago

$SLS Now 400% seems imminent! I mean how long can that BS go on for?

User Image cb5000calls Posted - 9 hours ago

$SLS 243.18K total volume and only 1.5 hours left to go hahahahah enjoy paying that now 406.16% borrow fee all weekend morons. Maybe you should have covered earlier in the week. One more day closer to forced short covering from massive REG SHO violations from illegal naked shorting. hahahahahahah must suck to be short. $NASDAQ $SPY $QQQ

User Image OK_USA Posted - 10 hours ago

$SLS stocks goes up and down. This is at the bottom. It's a waiting game. The ride up is imminent.

User Image BadDecisionz Posted - 10 hours ago

$SLS What’s another stock your holding that you absolutely believe should be priced higher? Grrr (Gorilla tech) 31 million market cap, with a 1.63 eps , ’billion dollar pipeline’ priced in 2.80’s currently.. analyst price target of $40

User Image bikechain Posted - 10 hours ago

$SLS I think this is “frozen” close to “here” until the IA at the IDMC unveil. Every day there’s no news I’m not expecting much in the way of price movement. “

User Image SusieLee Posted - 10 hours ago

$SLS This is the same bagholder that has lost a fortune on SLS . Every stock he picks is a loser $ASPI hahaha he is clueless

Analyst Ratings
Cantor Fitzgerald Overweight Nov 22, 23
Cantor Fitzgerald Overweight Sep 7, 23
Alliance Global Partners Buy Nov 15, 22
Cantor Fitzgerald Overweight Jun 28, 22
Cantor Fitzgerald Overweight Jul 21, 21
Maxim Group Buy Nov 15, 19
Alliance Global Partners Buy Apr 8, 19
Oppenheimer Outperform Nov 1, 18
Maxim Group Buy Jul 20, 18